2023
Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
Velez J, Karakala N, Tayebi K, Wickman T, Mohamed M, Kovacic R, Therapondos G, Kanduri S, Allegretti A, Belcher J, Regner K, Wentowski C. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1. Kidney360 2023, 4: e448-e456. PMID: 36763632, PMCID: PMC10278824, DOI: 10.34067/kid.0000000000000068.Peer-Reviewed Original ResearchConceptsHepatorenal syndrome type 1Mean arterial pressureSyndrome type 1HRS-1Baseline SCrMAP riseType 1Serum creatinineArterial pressureKidney functionDay 14Baseline mean arterial pressureMean mean arterial pressureMedian mean arterial pressureEnd-stage liver diseaseMultivariate logistic regression analysisFavorable renal outcomeOptimal MAP targetsUse of norepinephrineLogistic regression analysisGreater reductionMedian sCrNorepinephrine useVasoconstrictor therapyRenal outcomes
2021
Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS, Investigators H. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. American Journal Of Kidney Diseases 2021, 79: 737-745. PMID: 34606933, DOI: 10.1053/j.ajkd.2021.08.016.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeRespiratory adverse eventsPrimary end pointFirst-line therapyMean arterial pressureSympathetic nervous systemSynthetic vasopressin analogueAdvanced cirrhosisHRS reversalAldosterone systemKidney injuryLack of evidenceAdverse eventsMortality benefitPortal pressureArterial pressureFulminant formSplanchnic systemSignificant morbidityRenal vasculatureVasodilatory substancesApparent increased rateTerlipressinCONFIRM trials